Two Multiplex Assays That Simultaneously Identify 22 Possible Mutation Sites in the KRAS, BRAF, NRAS and PIK3CA Genes

被引:77
作者
Lurkin, Irene [1 ]
Stoehr, Robert [2 ]
Hurst, Carolyn D. [3 ]
van Tilborg, Angela A. G. [1 ]
Knowles, Margaret A. [3 ]
Hartmann, Arndt [2 ]
Zwarthoff, Ellen C. [1 ]
机构
[1] Erasmus MC, Josephine Nefkens Inst, Dept Pathol, Rotterdam, Netherlands
[2] Univ Erlangen Nurnberg, Inst Pathol, Erlangen, Germany
[3] St James Univ Hosp, Canc Res UK Clin Ctr, Leeds Inst Mol Med, Leeds LS9 7TF, W Yorkshire, England
来源
PLOS ONE | 2010年 / 5卷 / 01期
关键词
METASTATIC COLORECTAL-CANCER; RECEPTOR INHIBITOR CETUXIMAB; BLADDER-CANCER; COLON-CANCER; PANITUMUMAB; EXPRESSION; CORRELATE; SURVIVAL;
D O I
10.1371/journal.pone.0008802
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Recently a number of randomized trials have shown that patients with advanced colorectal cancer do not benefit from therapies targeting the epidermal growth factor receptor when their tumors harbor mutations in the KRAS, BRAF and PIK3CA genes. We developed two multiplex assays that simultaneously screen 22 nucleotides in the KRAS, NRAS, BRAF and PIK3CA genes for mutations. The assays were validated on 294 tumor DNA samples from patients with advanced colorectal cancer. In these samples 119 KRAS codon 12 and 13 mutations had been identified by sequence analysis, 126 tumors were wild-type for KRAS and the analysis failed in 49 of the 294 samples due to poor DNA quality. The two mutation assays detected 130 KRAS mutations, among which were 3 codon 61 mutations, and in addition 32 PIK3CA, 13 BRAF and 6 NRAS mutations. In 19 tumors a KRAS mutation was found together with a mutation in the PIK3CA gene. One tumor was mutant for both PIK3CA and BRAF. In summary, the mutations assays identified 161 tumors with a mutation, 120 were wild-type and the analysis failed in 13. The material cost of the 2 mutation assays was calculated to be 8-fold lower than the cost of sequencing required to obtain the same data. In addition, the mutation assays are less labor intensive. We conclude that the performance of the two multiplex mutation assays was superior to direct sequencing. In addition, these assays are cheaper and easier to interpret. The assays may also be of use for selection of patients with other tumor types.
引用
收藏
页数:6
相关论文
共 23 条
[1]   Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer [J].
Amado, Rafael G. ;
Wolf, Michael ;
Peeters, Marc ;
Van Cutsem, Eric ;
Siena, Salvatore ;
Freeman, Daniel J. ;
Juan, Todd ;
Sikorski, Robert ;
Suggs, Sid ;
Radinsky, Robert ;
Patterson, Scott D. ;
Chang, David D. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (10) :1626-1634
[2]   Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers [J].
Barault, Ludovic ;
Veyrie, Nicolas ;
Jooste, Valerie ;
Lecorre, Delphine ;
Chapusot, Caroline ;
Ferraz, Jean-Marc ;
Lievre, Astrid ;
Cortet, Marion ;
Bouvier, Anne-Marie ;
Rat, Patrick ;
Roignot, Patrick ;
Faivre, Jean ;
Laurent-Puig, Pierre ;
Piard, Francoise .
INTERNATIONAL JOURNAL OF CANCER, 2008, 122 (10) :2255-2259
[3]   Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies [J].
Benvenuti, Silvia ;
Sartore-Bianchi, Andrea ;
Di Nicolantonio, Federica ;
Zanon, Carlo ;
Moroni, Mauro ;
Veronese, Silvio ;
Siena, Salvatore ;
Bardelli, Alberto .
CANCER RESEARCH, 2007, 67 (06) :2643-2648
[4]   Prediction of Progression of Non-Muscle-Invasive Bladder Cancer by WHO 1973 and 2004 Grading and by FGFR3 Mutation Status: A Prospective Study [J].
Burger, Maximilian ;
van der Aa, Madelon N. M. ;
van Oers, Johanna M. M. ;
Brinkmann, Anke ;
van der Kwast, Theodorus H. ;
Steyerberg, Ewout C. ;
Stoehr, Robert ;
Kirkels, Wim J. ;
Denzinger, Stefan ;
Wild, Peter J. ;
Wieland, Wolf F. ;
Hofstaedter, Ferdinand ;
Hartmann, Arndt ;
Zwarthoff, Ellen C. .
EUROPEAN UROLOGY, 2008, 54 (04) :835-844
[5]   Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer [J].
Di Nicolantonio, Federica ;
Martini, Miriam ;
Molinari, Francesca ;
Sartore-Bianchi, Andrea ;
Arena, Sabrina ;
Saletti, Piercarlo ;
De Dosso, Sara ;
Mazzucchelli, Luca ;
Frattini, Milo ;
Siena, Salvatore ;
Bardelli, Alberto .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (35) :5705-5712
[6]   BRAF mutation in endometrial carcinoma and hyperplasia:: Correlation with KRAS and p53 mutations and mismatch repair protein expression [J].
Feng, YZ ;
Shiozawa, T ;
Miyamoto, T ;
Kashima, H ;
Kurai, M ;
Suzuki, A ;
Konishi, I .
CLINICAL CANCER RESEARCH, 2005, 11 (17) :6133-6138
[7]   Mosaicism of activating FGFR3 mutations in human skin causes epidermal nevi [J].
Hafner, Christian ;
van Oers, Johanna M. M. ;
Vogt, Thomas ;
Landthaler, Michael ;
Stoehr, Robert ;
Blaszyk, Hagen ;
Hofstaedter, Ferdinand ;
Zwarthoff, Ellen C. ;
Hartmann, Arndt .
JOURNAL OF CLINICAL INVESTIGATION, 2006, 116 (08) :2201-2207
[8]   A SNaPshot assay for the rapid and simple detection of four common hotspot codon mutations in the PIK3CA gene [J].
Hurst C.D. ;
Zuiverloon T.C. ;
Hafner C. ;
Zwarthoff E.C. ;
Knowles M.A. .
BMC Research Notes, 2 (1)
[9]  
HYNES NE, 2009, CURR OPIN CELL BIOL
[10]   PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab [J].
Jhawer, Minaxi ;
Goel, Sanjay ;
Wilson, Andrew J. ;
Montagna, Cristina ;
Ling, Yi-He ;
Byun, Do-Sun ;
Nasser, Shannon ;
Arango, Diego ;
Shin, Joongho ;
Klampfer, Lidija ;
Augenlicht, Leonard H. ;
Soler, Roman Perez ;
Mariadason, John M. .
CANCER RESEARCH, 2008, 68 (06) :1953-1961